Skip to main content
. 2021 Aug 18;27(21):5961–5978. doi: 10.1158/1078-0432.CCR-21-0986

Table 1.

Best objective response.

Best objective response TKI-naïve viral HCC, n = 15 TKI-naïve nonviral HCC, n = 11 TKI-experienced viral HCC, n = 6 TKI-experienced nonviral HCC, n = 4
Total evaluable (%) 15 (100) 11 (100) 6 (100) 4 (100)
Objective response (%) 4 (26.7) 1 (9.1) 0 0
 Complete response 2 (13.3) 0 0 0
 Partial response 2 (13.3) 1 (9.1) 0 0
Stable disease (%) 7 (46.7) 7 (63.6) 6 (100) 4 (100)
Progressive disease (%) 4 (26.7) 3 (27.3) 0 0